Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Stock Short Interest Report for October

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 141,864 shares, an increase of 313.3% from the September 30th total of 34,322 shares. Currently, 0.9% of the company’s stock are short sold. Based on an average daily trading volume, of 60,205 shares, the short-interest ratio is currently 2.4 days.

Institutional Trading of Radiopharm Theranostics

A hedge fund recently bought a new position in Radiopharm Theranostics stock. Hsbc Holdings PLC acquired a new stake in shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 191,624 shares of the company’s stock, valued at approximately $1,007,000. Hsbc Holdings PLC owned about 1.62% of Radiopharm Theranostics at the end of the most recent reporting period.

Radiopharm Theranostics Stock Performance

RADX stock opened at $1.11 on Friday. Radiopharm Theranostics has a 52-week low of $0.90 and a 52-week high of $16.25. The stock’s 50 day moving average is $1.61 and its two-hundred day moving average is $3.70.

Radiopharm Theranostics (NASDAQ:RADX) last released its earnings results on Friday, July 31st. The company reported ($0.81) EPS for the quarter. The firm had revenue of $0.49 million during the quarter. As a group, equities research analysts predict that Radiopharm Theranostics will post -3.23 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Radiopharm Theranostics in a research note on Thursday, October 15th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Radiopharm Theranostics presently has a consensus rating of “Hold” and an average price target of $11.00.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company focused on developing radiopharmaceutical products for the diagnosis and treatment of cancer. Its approach combines tumor-targeting molecules with radioactive isotopes to create imaging agents for positron emission tomography and therapeutic candidates designed to deliver radiation directly to cancer cells.

The company is developing a pipeline of diagnostic and therapeutic radiopharmaceuticals intended to address solid tumors and other difficult-to-treat cancers.